Showing Results for
- Academic Journals (33)
Search Results
- 33
Academic Journals
- 33
- Search Terms:
- 1From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedThere are currently no approved antifibrotic therapies for liver cirrhosis. Using three animal models of liver cirrhosis, Sato and colleagues showed that injection of vitamin A-coupled liposomes carrying small...
- 2From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedIn another court battle over the anticoagulant Lovenox (enoxaparin), a US Court of Appeal for the Federal Circuit has affirmed a district court decision, holding that Sanofi-Aventis's patent is unenforceable. The...
- 3From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedIn March 2008, bendamustine hydrochloride (Treanda; Cephalon), a DNA alkylating anticancer agent, was approved by the US FDA for the treatment of chronic lymphocytic leukaemia. Chronic lymphocytic leukaemia (CLL),...
- 4From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedAntipsychotics remain the current standard of care for mental disorders including schizophrenia (~1% prevalence) and bipolar mania (~39% prevalence), and generate over US$16 billion worldwide in annual sales (FIG. 1;...
- 5From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedIn the media furore following the FDA's issuance of an approvable letter for Dendreon's prostate cancer vaccine Provenge (Sipuleucel-T) in May last year, attention focused on the need for more clinical efficacy data....
- 6From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedMicrobial lung infections are a major cause of morbidity in patients with cystic fibrosis. Teichgraber and colleagues showed that deficiency of Cftr in mice resulted in the accumulation of cellular ceramide in the...
- 7From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedAbstract | Legislation to create a regulatory pathway for follow-on biologics is currently being considered by the United States Congress. A critical issue in this respect is the period of data exclusivity for innovator...
- 8From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedMET tyrosine kinase has dual roles as an adjuvant, pro-metastatic gene for some tumour types and as a necessary oncogene for others, making it a promising candidate for targeted cancer treatment. In their Review on p504,...
- 9From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedThe Canadian Government is proposing amendments to its Patented Medicines Regulations--and in doing so over-riding a Supreme Court decision--which could result in longer patent protection for innovator drugs on the...
- 10From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedNovo Nordisk has donated a license for access to its chemical library to the World Health Organization (WHO) and Chinese Academy of Sciences to identify new drug candidates for tropical diseases. The lowdown: The small...
- 11From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedThe FDA's request for Genzyme to submit a new biologics license application (BLA) for its Pompe disease drug Myozyme raises questions for follow-on product approval in the United States The lowdown: In Apri1 2006,...
- 12From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedAllan Marchington, Ph.D., Partner, Apposite Capital, London, UK. A lunch with a venture capitalist colleague was the catalyst that led to Allan Marchington becoming a founding partner of Apposite Capital, a US$200...
- 13From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedInternational consortium of genome research organizations to catalogue cancer. The lowdown: The International Cancer Genome Consortium (ICGC), launched at the end of April this year, aims to generate a list of 50 cancer...
- 14From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedPresident and CEO of the Biotechnology Industry Organization (BIO), Washington DC, USA. Since his appointment in 2005, James Greenwood has contributed to BIO becoming a world-class advocacy organization, playing a...
- 15From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedIn 2006, the US National Institutes of Health (NIH) launched the Clinical and Translational Science Awards (CTSA) programme--a major part of its ongoing effort to accelerate the translation of biomedical research into...
- 16From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedAbstract Lipids are vital components of many biological processes and crucial in the pathogenesis of numerous common diseases, but the specific mechanisms coupling intracellular lipids to biological targets and...
- 17From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedPfizer has launched the Insulin Resistance Pathways Project to find new drug targets to treat diabetes. The lowdown: The potential of systems-biology approaches to help guide drug discovery and development is attracting...
- 18From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedThe World Health Organisation (WHO)'s Intergovernmental Working Group on Public Health, Innovation and Intellectual Property recently met in Geneva to discuss the R&D of treatments for diseases that disproportionately...
- 19From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedGenzyme and ISIS have announced that a reduction in LDL-cholesterol is an acceptable surrogate endpoint for the accelerated approval of their familial hypercholesterolaemia drug. The lowdown: Following the media interest...
- 20From: Nature Reviews Drug Discovery. (Vol. 7, Issue 6) Peer-ReviewedFrom June 2008 onwards the UK's National Institute of Health and Clinical Excellence (NICE)will open its standing advisory committee meetings to observers from the public and press. The lowdown: In the UK, NICE is...